We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




Novel Macrophage Nanoparticles Created as Sepsis Treatment

By LabMedica International staff writers
Posted on 16 Jan 2018
Print article
Image: An artist illustration of nanoparticles coated with macrophage cell membranes (Photo courtesy of Nanomaterials & Nanomedicine Laboratory, University of California, San Diego).
Image: An artist illustration of nanoparticles coated with macrophage cell membranes (Photo courtesy of Nanomaterials & Nanomedicine Laboratory, University of California, San Diego).
A novel approach for treating sepsis is based on nanoparticles (so-called nanosponges) coated with cell membranes isolated from immune macrophages.

Sepsis is a life-threatening condition that arises when the body's response to infection causes injury to its own tissues and organs. Sepsis is caused by an immune response triggered by an infection. Most commonly, the infection is bacterial, but it may also be from fungi, viruses, or parasites. Common locations for the primary infection include lungs, brain, urinary tract, skin, and abdominal organs.

Currently, there are no effective clinically available sepsis treatments, and care remains primarily supportive. In an effort to develop an effective sepsis treatment, investigators at the University of California, San Diego (USA) fabricated a novel type of macrophage biomimetic nanoparticle or nanosponge. The nanoparticles, made by wrapping polymeric cores with cell membrane derived from macrophages, possessed an antigenic exterior the same as the source cells.

The investigators reported in the October 24, 2017, online edition of the journal Proceedings of the [U.S.] National Academy of Sciences that by acting as macrophage decoys, these nanoparticles bound and neutralized endotoxins that would otherwise have triggered immune activation. In addition, these macrophage-like nanoparticles sequestered proinflammatory cytokines and inhibited their ability to potentiate the sepsis cascade.

In a mouse Escherichia coli bacteremia model, treatment with macrophage mimicking nanoparticles, termed M-Phi-NPs, reduced proinflammatory cytokine levels, inhibited bacterial dissemination, and ultimately conferred a significant survival advantage to infected mice.

"A wide range of endotoxins and pro-inflammatory cytokines naturally bind to macrophage cell membranes, so these nanosponges serve as universal traps for a broad spectrum of sepsis-causing molecules," said senior author Dr. Liangfang Zhang, professor of nanoengineering at the University of California, San Diego. "They can work across different bacterial genus, species and strains, and since they are covered in actual macrophage cell membranes, they can pass as the body's own immune cells and circulate the bloodstream without being evicted."

Related Links:
University of California, San Diego

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A network of inflammatory molecules may act as biomarker for risk of future cerebrovascular disease (Photo courtesy of 123RF)

Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease

Cerebral small vessel disease is a common cause of stroke and cognitive decline, particularly in the elderly. Presently, assessing the risk for cerebral vascular diseases involves using a mix of diagnostic... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The Aperio GT 450 DX has received US FDA 510(k) clearance (Photo courtesy of Leica Biosystems)

Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization

Digital pathology is rapidly becoming a key aspect of modern healthcare, transforming the practice of pathology as laboratories worldwide adopt this advanced technology. Digital pathology systems allow... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.